Live feed21:45:00·1202dPRReleasevia QuantisnowAcadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderByQuantisnow·Wall Street's wire, on your screen.ACAD· ACADIA Pharmaceuticals Inc.Health Care
